Skip to main content

Daily editionStrategic Internet IntelligenceJul 24, 2026

Intelligence Directory

Sign In Register

Disciplined intelligence layer in internet infrastructure, governance, and digital capital markets.

Governance

RIR Watchdog
Case File
Number Resource Society
ICANN
IETF
History of Internet
Network Operator Group (NOGs)
RIR Directory

Market

People
Trends
Companies

Membership

Leadership Alliance
Strategic Circle

Framework

Clarity over amplification

Evidence over sentiment

Systems over noise

About BTW Contact Us Join Our Team Privacy Policy Terms of Service

Home
Internet Infrastructure Intelligence Directory
Theranos, Inc.

Intelligence Directory

Theranos, Inc.

Theranos, Inc. is connected with ASN/IP network resources in Unavailable.

Identity: Theranos, Inc., Institution

Jump within this record

SectionWhat to know first
SectionBasic information
SectionLocations
SectionOther network resources
SectionPeople and contacts
SectionRegistry and related records
SectionRelated research

Directory Home Organizations Resources Services Locations People

Organizations Company Registry Operator Institution Government body Alliance Standards body NGO

Organization

Theranos, Inc.

Theranos, Inc. is connected with ASN/IP network resources in Unavailable.

Institution

What to know first

IdentityTheranos, Inc., InstitutionHigh confidence

Basic information

Display nameTheranos, Inc.High confidence
Legal typeInstitutionHigh confidence
Directory categoryInstitutionHigh confidence
Last updatedJul 17, 2026High confidence

Locations

Geography scopeNorth AmericaHigh confidence
Other infrastructure servicesNorth AmericaMedium confidence

Other network resources

Service platformTheranos, Inc. Other infrastructure services · North AmericaUnrated

People and contacts

Contacts

Policy

Medium confidence

Available contact typesPolicyMedium confidence

Registry and related records

Coverage contextTheranos made laboratory validation and regulatory evidence a diagnostic-safety accountability test, Theranos did not become a diagnostic-safety case because a small blood sample was an illegitimate research goal. It became one because a commercial laboratory reported patient results and raised investment capital while the evidence available to test its broad claims remained fragmented, restricted, or materially inconsistent with what outsiders were told. Reconstructing that sequence before assigning responsibility shows where practical control sat: with executives who authorized claims and expansion, laboratory leaders who controlled release of results, technical teams who generated validation and quality-control evidence, commercial partners and directors who could demand independent proof, and regulators whose separate mandates covered the laboratory, devices, securities, and later criminal conduct.Medium confidence

Related research

Primary articleTheranos made laboratory validation and regulatory evidence a diagnostic-safety accountability testHigh confidence

Continue browsing

Organizations Resources People